Phase 2 Clinical Trial in Locally Advanced Pancreatic Cancer (LAPC) is Recruiting Patients
March 8, 2018 – Silenseed, a leading company in targeted treatments for solid tumors, announced the recruitment of the first patient in the company’ SLSG12D-P2 Phase 2 clinical trial in Locally Advanced Pancreatic Cancer (LAPC). SLSG12D-P2 now is opened, recruiting eligible patients in the Memorial Sloan Kettering Cancer Center in New York, USA. Efficacy evaluations […]